Financial PerformanceZymeworks recorded a net loss of $0.31 per share, wider than the previously forecasted net loss of $0.12 per share, primarily due to lower-than-expected revenue.
Stock PerformanceShares are down compared to the sector, due to limited internal catalysts and high expectations for zani's Ph3 trial in GEA.
Trial RisksRisks include clinical trial failures, insufficient efficacy, and inability to obtain timely approval of zanidatamab.